In ECs, UDCA inhibits endothelial dysfunction by inhibiting ER stress, reducing RAGE expression, inhibiting the inflammatory response (including NF-κB activation), and suppressing ROS production, by increasing Nrf2 levels under hyperglycemic conditions. Here, NFKB1 is linked to endothelial dysfunction.